Leap Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Cypherpunk Technologies Inc. reports a significant net income for 2025 driven by an unrealized gain on its Zcash holdings, following a strategic pivot to privacy technology while scaling back its biotechnology operations.
Leap Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including sirexatamab and FL-501.
Leap Therapeutics' 2023 annual report details significant R&D spending, clinical trial advancements, and a net loss, while emphasizing the potential of their drug candidates.